[Alpha1-antitrypsin deficiency].
Alpha(1)-antitrypsin deficiency is characterized by a pathologic reduction of the serum concentration of alpha(1)-antitrypsin, the most important antiprotease in man. It is one of the most common hereditary diseases in Caucasians. Approximately 2% of obstructive airway diseases are caused by alpha(1)-antitrypsin deficiency. Patients above 35 years may develop lung emphysema, especially in the lower lobes. Symptoms are those of chronic obstructive pulmonary disease such as cough, sputum expectoration, and progressive dyspnoea. Patients with homozygous defect often develop cholestatic hepatitis in the neonatal period. However, only few adult patients develop chronic liver disease up to liver cirrhosis with an elevated risk for malignant liver tumors. The diagnostic hallmark is the reduced serum concentration of alpha(1)-antitrypsin while genetic testing proves the defect. An early recognition of the disease is decisive for prophylactic and therapeutic measures. Smoking should be stopped immediately. Treatment of lung disease includes physiotherapy, antiobstructive and antiinflammatory medication, augmentation with human alpha(1)-antitrypsin and lung surgery including lung transplantation. Liver toxins should be avoided. Besides experimental therapeutic approaches, liver disease can only be treated by liver transplantation.
Köhnlein
T
T
Klinik für Pneumologie, Medizinische Hochschule Hannover, Hannover, Deutschland.
Rifai
K
K
D000328:Adult; D004252:DNA Mutational Analysis; D006720:Homozygote; D006801:Humans; D007231:Infant, Newborn; D008105:Liver Cirrhosis, Biliary / Q000175:diagnosis / Q000235:genetics; D008113:Liver Neoplasms / Q000175:diagnosis / Q000235:genetics; D011379:Prognosis; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy; D019896:alpha 1-Antitrypsin Deficiency / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy